Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma

Inclusion Criteria: 1. Stage 4 or unresectable stage 3 metastatic melanoma with or without measurable disease 2. Age 18-70 years old 3. Adequate pulmonary and cardiac function for high-dose IL-2 4. PS 0-2 5. Previous ipilimumab therapy will not exclude patients, but patients with previous ipilimumab will have separate efficacy analysis Exclusion Criteria: 1. Brain metastases 2. Creatinine \> 2x ULN; bilirubin \> 3, WBC \< 3500, Platelets \< 100,000, Hgb \< 9 3. Another active malignancy 4. Gastrointestinal tract metastases except rectal metastases or primary are allowable 5. Previous therapy for metastatic disease with chemotherapy of duration over 3 months or with high-dose interleukin-2 6. History of colitis or autoimmune disease such as lupus or rheumatoid arthritis 7. Bevacizumab-related contraindications: Hemoptysis or history of severe bleeding, uncontrolled hypertension, proteinuria with protein/creatinine ratio \> 1, acute myocardial infarction within 6 months